Daily Archives: May 17, 2022

Albany NY, United States: Cancer Genome Sequencing Market: Snapshot

Cancer genome sequencing market is anticipated to witness exponential growth during the forecast period of 2021-2031 due to emergence of next-gen sequencing technology that is offering exclusive sensitivity and resolution. Cancer genome sequencing is developing at a faster pace and can be altered in their gross chromosomal structure through amplification, Furthermore, the efforts to make it cost-effective and accurate, may generate ample revenue opportunities for the cancer genome sequencing market.

On the basis of technology the cancer genome sequencing market can be segmented into second generation technology platforms and third generation technology platforms. Further, the second generation technology platform can be classified into solid sequencing, pyro sequencing, and bridge amplification sequencing technology. The third generation technology platforms include single molecule real time sequencing, Nanopore sequencing, florescent resonant energy transfer sequencing.

The in-depth analysis performed by the team of analysts TMR provides all important information about the current market scenario. It assists the CXOs to make proper decisions regarding investments and collaborations. The factors that are taken into consideration are the market trends, key drivers, restrains, opportunities, and challenges in the cancer genome sequencing market.. The impact of COVID-19, in particular, is also covered in this report.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4619

Cancer Genome Sequencing Market: Key Trends and Opportunities

The rising incidences of cancer across the globe has led to the development of cancer genome sequencing for detecting copy number alterations, exome wide base substitutions, and translocations in all cancer cells easily. Taking all these aspects into consideration, the global cancer genome sequencing market may grow substantially. Significant rise in the geriatric population and the escalating rate of patients diagnosed with chronic diseases and cancer are increasing the demand for the cancer genome sequencing market. Thus, these aspects are likely to bring multiple growth opportunities for the market.

Cancer genome sequencing helps in the proper diagnosis of tumors irrespective of its location. It also helps in viewing the whole genome and has the ability to eliminate the requirement of having updates regarding patients history. Further, the personalization of cancer treatment is likely to be a growth booster for the cancer genome sequencing market in the coming years.

Development in computing power has led to wide range of applications in cancer genome sequencing market such as personalized medicine, detection of biomarker, and others. In addition, the improved and quick computing technologies in anticancer therapies and pharmacogenomics are likely to create multiple opportunities for the cancer genome sequencing market.

Get COVID-19 Analysis on Cancer Genome Sequencing Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=4619

Cancer Genome Sequencing Market: Competitive Insights

The key players are trying hard to make the sequencing technology cost effective by finding out alternatives that can be comparatively inexpensive. One such alternative is targeted gene sequencing method which is affordable and effective.

The key players are investing in research and development activities to innovate new technologies to upgrade their products. The key players are analyzing the prevailing opportunities to strengthen their market presence. The investments in R&D activities have led to replacing the traditional tools of genomics with technologically advanced cancer genome sequencing applications.

The key players operating in the Cancer genome sequencing market are Ambry Genetics, BGI Americas Corporation, Beckman Coulter Genomics, Illumina, Inc., Pacific Biosciences, and Pacific Biosciences

Make an Enquiry before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=4619

Cancer Genome Sequencing Market: Regional Prospects

Cancer genome sequencing market can be segmented into North America, Europe, Asia Pacific, and LAMEA based on the regions. North America is anticipated to show a high growth trajectory in the cancer genome sequencing market due to the increasing awareness about cancer genome sequencing applications. Europe also may create multiple growth avenues for the global market owing to the rigorous R&D activities being conducted in this region.

This upcoming business intelligence report is intended to be a one-stop market research solution to guide organizations in taking timely and effective decisions for their business growth. The ongoing study is the culmination of our deep expertise on data science methods, combined with an unparalleled understanding of the external environment and analysis of the industries. Each of the reports by TMR aims at offering a detailed scrutiny of the value chain of our current and prospective customers, takes them from identifying value propositions, and subsequently assist their business executives to implement right strategies to create customer value. We believe that creating and sustaining the customer value is the key pivot on which business executives can create profits for their organizations and increase the market shares, continuously and with sustainability.

Each of our touchpoints through which we engage with the organization/enterprise during the primary research enables us to understand the internal environment it operates in and the ways in which the external environment influences its growth.

Browse more Reports by Transparency Market Research:

Digital Pathology Market: Rising awareness about digital pathology and increase in demand for advanced technology are the factors likely to boost the growth of digital pathology market. Moreover, high incidence and prevalence of cancer and other chronic diseases is poised to escalate the growth of digital pathology market.

Mechanical Ventilators Market: The global mechanical ventilators market is estimated to witness increased sales during forecast period. This increased sales rate is attributed to growing older population and rising cases of respiratory diseases. Mechanical ventilator is an artificial breathing device majorly used for treating patients with severe medical conditions.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Read the original:
Cancer Genome Sequencing Market: Rising Incidences of Cancer across the Globe to Drive the Market - BioSpace

NEW YORK While the human germline appears to be relatively impervious to acquiring many mutations, some genetic vulnerabilities or paternal exposure to chemotherapy can prompt pronounced de novo mutations, new research has found.

"Our results suggest that the germline is well protected from mutagenic effects, hypermutation is rare, the number of excess mutations is relatively modest, and most individuals with a hypermutated genome will not have a genetic disease," senior author Matthew Hurles, a researcher at the Wellcome Sanger Institute, and his colleagues wrote in Nature on Wednesday.

Following prior studies in mice with specific DNA repair mutations or mutagenic exposures, the team set out to search for signs of hypermutation in the human germline, where far less is known about individuals at the high end of the germline mutation spectrum.

Using exome or whole-genome sequence data for nearly 21,900 parent-child sets from the 100,000 Genomes Project or the Deciphering Developmental Disorders project including families with children suspected of having rare genetic conditions the researchers found a dozen participants who had up to seven times as many de novo single-base mutations in their germline than the median of other individuals.

In nine of the 12 individuals, the team traced the hypermutation back to their fathers. In some families, individuals carried damaging alterations affecting DNA repair genes, while others had germline mutation signatures linked to platinum-based chemotherapy, including children born to fathers who went through cancer treatment prior to conceiving children.

When the investigators explored the latter results further using data for dozens of parents from the 100,000 Genomes Project who had a history of cancer treatment, they found germline hypermutation in children born to two of 27 fathers treated for cancer. They also detected a nominal increase in de novo single-nucleotide changes in children born to mothers with a cancer treatment history, though the women also tended to be older than unaffected mothers when their children were born.

Among other implications, the results suggest that there may be a benefit for male cancer patients to preserve sperm prior to chemotherapy treatment, particularly for men who wish to have children in the future. At the moment, measures are typically offered to protect against chemotherapy-related infertility.

"Clinically, patients receiving chemotherapy who might want to go on to have children in the future are often offered the opportunity to freeze sperm prior to treatment as part of standard of care in the UK," Hurles explained in an email, adding that "it is not just cancer patients that receive mutagenic chemotherapies; these drugs are also given for non-cancer conditions, for example for immune suppression in some auto-immune disorders."

Although the evidence available so far suggests that the germline "generally appears to be well protected from large increases in mutation rate," the authors wrote, Hurles and his colleagues called for additional studies that include individuals exposed to a broader set of potential mutagens, and their family members, to find more modest germline mutation signatures and ties between genes and other environment factors.

"I anticipate that the publication of our study will trigger a range of future studies looking into the germline effects of a range of mutagens, including many chemotherapies," Hurles wrote. "I also think that more studies will identify genetic causes of hypermutation, and through these studies, we will learn more about the differences between the soma and the germline in terms of how mutations are minimized."

Originally posted here:
Most People With Hypermutated Genome Obtain Excess Mutations from Father, Study Finds - GenomeWeb

Researchers at EMBL Heidelberg found that inversions in the human genome are more common than previously thought, which impacts our understanding of certain genetic diseases.

Our DNA serves as a blueprint for the cellular machinery that allows cells, organs, and even whole organisms to work. However, mutations in our DNA can cause genetic illnesses. Point mutations at a single site, as well as deletions, duplications, and inversions, are examples of such DNA mutations.

Inversion refers to a piece of DNA inverting its orientation in the genome. Because inversions are more difficult to analyze than other forms of mutations, they are poorly understood. Scientists from EMBL Heidelberg, working with colleagues from the University of Washington in the United States and Heinrich Heine University Dsseldorf in Germany, have determined that inversions are one of the most common mutational processes in humans.

The researchers uncovered how inversions are formed and investigated in detail a set of 40 inversions that form recurrently in the genome, where the DNA sequence flips back and forth. These flip-flopping inversions typically lie in regions linked to the development of certain human diseases called genomic disorders.

We found that inversions form at a much higher rate than previously thought. In humans, at least 0.6% of the genome repeatedly changes direction, making inversion one of the fastest mutational processes in humans, said Jan Korbel, EMBL Senior Scientist and Head of Data Science. At these sites, the genome is not stable the direction of the DNA code continues to switch back and forth.

These unstable areas are home to the many essential human genes. Scientific studies of long-distance gene regulation or epigenetics must now take into account this flipping behavior of genomic regions.

Artistic interpretation of inversions in the human genome. Credit: Isabel Romero Calvo/EMBL

Inversions are also relevant for the development of human diseases, such as developmental delays in children or neuropsychiatric disorders in adults. Despite their importance, these regions have been very difficult to study before because of their complexity. Showing that these inversions indeed flip-flop back and forth required a new set of computational methods, said Tobias Marschall, Director of the Institute of Medical Biometry and Bioinformatics and the Heinrich Heine University Dsseldorf. We can now provide human geneticists with a new tool to understand the origin of disease in their patients.

Evan Eichler, group leader at the University of Washington, said: We showed for the first time that inversions can be associated with rare genomic rearrangements found in pediatric autism, developmental delay, and epilepsy. The question now is why? We hypothesize that certain configurations at the flanks of the inversions either predispose or protect individuals and their offspring from disease-associated rearrangements. This could have a practical application in the clinic, where it could be used to identify families at risk for developing these disorders.

Reference: Recurrent inversion polymorphisms in humans associate with genetic instability and genomic disorders by David Porubsky, Wolfram Hps, Hufsah Ashraf, PingHsun Hsieh, Bernardo Rodriguez-Martin, Feyza Yilmaz, Jana Ebler, Pille Hallast, Flavia Angela Maria Maggiolini, William T. Harvey, Barbara Henning, Peter A. Audano, David S. Gordon, Peter Ebert, Patrick Hasenfeld, Eva Benito, Qihui Zhu, Human Genome Structural Variation Consortium (HGSVC), Charles Lee, Francesca Antonacci, Matthias Steinrcken, Christine R. Beck, Ashley D. Sanders, Tobias Marschall, Evan E. Eichler and Jan O. Korbel, 6 May 2022, Cell.DOI: 10.1016/j.cell.2022.04.017

Read more here:
Horrifying Discovery: Scientists Find That DNA Mutations Are More Common Than Previously Thought - SciTechDaily

Excision BioTherapeutics

SAN FRANCISCO, May 17, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that preclinical and bioinformatic data showing robust and specific editing of HIV proviral DNA with EBT-101 will be featured in an upcoming poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, which is taking place at the Walter E. Washington Convention Center in Washington, D.C.

EBT-101 is a unique, clinical-stage, in vivo CRISPR-based therapeutic designed to functionally cure HIV infections after a single intravenous infusion. It employs an adeno-associated virus (AAV) to deliver CRISPR-Cas9 and dual guide RNAs targeting three sites within the HIV genome. Bioinformatic analyses featured in the ASGCT poster compare these EBT-101 target sites against the human reference genome and show no identical matches. Moreover, there are no candidate off-target sites in the human reference genome with only one or two differences from EBT-101 target sites, and only a single candidate off-target site with three differences. These findings predict a lack of off-target activity for EBT-101, which has been confirmed by in vitro and in vivo studies showing HIV excision without unintended editing.

Taken together, the data being presented at ASGCT highlight the key advantages of Excisions novel therapeutic approach, said TJ Cradick, Ph.D., Chief Scientific Officer of Excision and lead author on the poster. By leveraging our in-silico design platform, we carefully crafted EBT-101 to minimize viral escape and off-target effects by cutting at three target sites that are specific to the HIV genome. Latent viral reservoirs were eradicated in in multiple disease models and resulted in functional cures in transgenic mice. We are now working to build on these results through the advancement of EBT-101s recently initiated Phase 1/2 clinical trial, and look forward to discussing our program with the scientific community at the upcoming ASGCT meeting.

Story continues

The ASGCT poster, entitled, EBT-101 achieves robust CRISPR-based editing of HIV proviral DNA without detectable off-target effects, will be presented today from 5:30 6:30 PM ET during the Hematologic and Immunologic Disease II poster session (Board No. TU-205). The poster was authored in collaboration with researchers from institutions including Temple University and Dartmouth-Hitchcock Medical Center. A copy of the poster will be posted to the Excisions website following its presentation at the meeting.

About EBT-101

EBT-101 is a unique, in vivo CRISPR-based therapeutic designed to functionally cure HIV infections after a single intravenous infusion. It employs an adeno-associated virus (AAV) to deliver CRISPR-Cas9 and dual guide RNAs targeting three sites within the HIV genome. This novel approach enables the excision of large portions of the HIV genome, thereby minimizing potential viral escape. EBT-101 is being evaluated in clinical trials and is the only therapeutic candidate in history to achieve functional cures of HIV in animal models.

About Excision BioTherapeutics, Inc.

Excision BioTherapeutics, Inc. is a biotechnology company developing CRISPR-based therapies as potential cures for viral infectious diseases. Excision unites next-generation CRISPR nucleases with a novel gene editing approach and has become the first and only company in history to cure HIV with a therapeutic in an animal model. EBT-101, the companys lead program intended to cure HIV with a single IV infusion, is being evaluated in clinical trials. Excisions pipeline includes one-time potential cures for Herpes Virus, JC Virus, which causes PML, and Hepatitis B virus. The Companys foundational technologies were developed in the laboratories of Dr. Kamel Khalili at Temple University and Dr. Jennifer Doudna at University of California, Berkeley. For more information, please visit http://www.excision.bio.

Contacts:

InvestorsJohn FrauncesLifeSci Advisors917-355-2395jfraunces@lifesciadvisors.com

MediaRobert Flamm, Ph.D.Burns McClellan, Inc.212-213-0006 ext. 316 / 364rflamm@burnsmc.com

Continued here:
Excision BioTherapeutics to Present Preclinical and Bioinformatic Data Showing Robust and Specific Editing of HIV Proviral DNA with EBT-101 at the...

SAN FRANCISCO - May 16, 2022 - (

)

The Ministry of the Economy launches a strategic initiative aimed at assessing the Luxembourg start-up ecosystem in order to identify further steps to bring the ecosystem towards a next level of development over the upcoming years.

The Luxembourg start-up ecosystem has been on a constant rise over the past decade. In its latest mapping (www.startupluxembourg.com/why-luxembourg/ecosystem-mapping), Luxinnovation, the Luxembourg's national innovation agency, identified more than 500 start-ups active in developing and offering innovative digital and data driven solutions, mostly in the key fields of economic diversification.

Luxembourg has an established history of empowering innovators, entrepreneurs, and investors to implement their vision and contribute to economic diversity through regional and globally competitive enterprises.Given Luxembourg's central position in the European single market, highly advanced legislative and regulatory frameworks and competitive digital infrastructure, the start-up ecosystem attracts innovative professionals and start-up companies from all over the world.

In order to gain a more granular view of the Luxembourg start-up ecosystem and its international positioning, an assessment and a benchmarking will start in May. This assessment and benchmarking will provide a thorough qualitative and quantitative understanding of the Luxembourg start-up ecosystem, based on data analysis, information gathered from the start-up community and interviews with key stakeholders. The study will provide relevant comparisons with international peers, highlighting potential future development opportunities as well as ecosystem success factor strengths and gaps.

Startup Genome, a leading research and policy advisory organization specialized in the analysis of start-up ecosystems was chosen to carry out this assessment and benchmarking in close collaboration with the dedicated team at the Ministry of the Economy and at Luxinnovation. In this process, Startup Genome will leverage its experience of over 200 ecosystems worldwide and the knowledge and data gathered through its yearlyGlobal Startup Ecosystem Report (GSER).

Within the context of the study and in order to collect the feedback from the start-up community, Startup Genome will reach out to entrepreneurs with a dedicated survey. Start-ups and entrepreneurs willing to take the survey and give their input can find more information on http://www.startupluxembourg.com.

The results of the study as well as a consultation process with key stakeholders of the ecosystem will be taken into account for the elaboration of a strategic roadmap for the further development of the Luxembourg start-up ecosystem.

Press Release Service by

Original Source:

View original post here:
Startup Genome and the Ministry of the Economy Launch a Study to Assess and Benchmark the Luxembourg Star - Benzinga